Gliclazide Extended-Release Tablets can be used in combination with Engeletin, but need to pay attention to blood glucose monitoring under the guidance of a doctor to prevent hypoglycemia. Gliclazide extended-release tablets belong to the sulfonylurea class of oral hypoglycemic drugs, suitable for patients with mild and moderate type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus) with unsatisfactory efficacy of dietary control and physical exercise for 2-3 months, whose pancreatic islet B-cells have a certain degree of insulin-secreting function, and who do not have acute complications (infections, traumas, ketoacidosis, hyperosmolar hyperglycemic coma, etc.). Adverse reactions to gliclazide extended-release tablets are hypoglycemia, sweating, moist skin, anxiety, nausea, vomiting, rash, itching and other adverse reactions. The drug is contraindicated in allergy to the product, type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic insufficiency, and lactation. Engeletin is a sodium-glucose cotransporter 2 inhibitor that promotes glucose excretion from the urine by decreasing glucose reabsorption in the kidneys. It is used in the treatment of type 2 diabetes mellitus and can be used in combination with sulfonylureas. Adverse reactions such as hypoglycemia and genitourinary tract infections have been seen with empagliflozin. The drug is contraindicated in people with a history of severe hypersensitivity reactions to the product, end-stage renal disease or dialysis, and severe renal impairment. It is not recommended for use in type 1 diabetes. Gliclazide Extended-Release Tablets and Engeletin belong to different types of hypoglycemic drugs, which have different pharmacological effects and can be used in combination. However, the combined use of drugs should pay attention to monitoring blood glucose to avoid hypoglycemia. Under the guidance of the doctor should be reasonable use of drugs.